Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

The effects of systemic isotretinoin on ocular surface and meibomian glands

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cornea: Medical

Venue: Poster Village: Pod 2

First Author: : M.Irkec TURKEY

Co Author(s): :    N. Acar   S. Kocabeyoglu   Z. Atakan                 

Abstract Details


To evaluate the effects of systemic isotretinoin therapy on the ocular surface and meibomian glands (MG) in patients with cystic acne.


Hacettepe University School of Medicine, Department of Ophthalmology Hacettepe University School of Medicine, Department of Dermatology


Twenty patients with cystic acne and 20 age and sex matched healthy control subjects were included the study. For all the participants, the tear break-up time (BUT), lissamine green (LG) staining, Schirmer test, meibography of the upper lid for grading meibomian gland dysfunction (MGD), and in vivo confocal microscopy (IVCM) were performed before and after the first and third months of systemic isotretinoin therapy. Ocular surface disease index (OSDI) questionnaire scores were also noted for each subject. Mann Whitney U test, Friedman’s two way analysis of variance and Related Samples Cochran’s Q test were used for data analysis.


There was no statistically difference in the mean age between two groups (24.4±7.4 for patient and 26.5±6.8 for control group) (p=0.106). Significant differences were found in MGD grading and the distribution of epithelial cell density in patient group between before and after the treatment (p< 0.001 and p=0.002, respectively). The number of long nerve fibers between patients and control group was found to be statistically different (3.15±1.1 vs 3.75±0.78, p=0.043).


This study showed that systemic isotretinoin treatment affects ocular surface and meibomian glands in patients with cystic acne.

Financial Disclosure:


Back to previous